NB
Therapeutic Areas
Innate Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lacutamab (IPH4102) | Cutaneous T-cell Lymphoma (CTCL), Sézary Syndrome | Phase 3-ready |
| IPH4502 | Solid Tumors (Nectin-4 expressing) | Phase 1 |
| Monalizumab | Non-Small Cell Lung Cancer (NSCLC) | Phase 3 |
| IPH6501 | B-cell Non-Hodgkin's Lymphoma (NHL) | Phase 1/2 |
| IPH6101 / SAR'579 | Acute Myeloid Leukemia (AML) & other CD123+ malignancies | Phase 1/2 |
| IPH6401 / SAR'514 | Multiple Myeloma (MM) & other BCMA+ malignancies | Phase 1/2 |
| IPH5201 | Solid Tumors (targeting CD39) | Phase 1 |
| IPH5301 | Solid Tumors (targeting CD73) | Preclinical |
Leadership Team at Innate Pharma
JD
Jonathan Dickinson
Chief Executive Officer
YM
Yannis Morel
Executive Vice President, Chief Operating Officer
SQ
Sonia Quaratino
Executive Vice President, Chief Medical Officer
FL
Frédéric Lombard
Senior Vice President, Chief Financial Officer
EV
Eric Vivier
Chief Scientific Officer
IS
Irina Staatz-Granzer
Chairwoman of the Board of Directors
PB
Pascale Boissel
Vice Chairperson of the Board of Directors
CI
Christian Itin
Board Member